What testing is required when considering the CCR5 antagonist agent Maraviroc?
The FDA states that tropism testing with a highly sensitive tropism assay is required for the appropriate use of maraviroc (1). Maraviroc is the first FDA-approved drug in a class of HIV drugs called entry and fusion inhibitors.
What class of drug is maraviroc?
Maraviroc is used along with other medications to treat a certain type of human immunodeficiency virus (HIV) infection in adults and children who weigh at least 4.4 lb (2 kg). Maraviroc is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood.
What does raltegravir interact with?
It is likely that the same dose recommendation will be applicable when raltegravir needs to be combined with other strong UGT inducers such as phenytoin and phenobarbital. Raltegravir is better absorbed in an environment with a higher pH and hence a drug-drug interaction study with an acid reducing agent was indicated.
Does maraviroc weaken your immune system?
Maraviroc affects your immune system and may possibly increase your risk of developing infections or cancer. Ask your doctor about this risk. Tell your doctor if you are pregnant, and use your medications properly to control your infection.
What result is required for maraviroc to be considered appropriate for use?
Maraviroc should only be used in people whose strain of HIV uses the CCR5 coreceptor. Maraviroc is not recommended for people whose HIV uses the CXCR4 coreceptor or both the CCR5 and CXCR4 coreceptors. Your health care provider will do a blood test to see whether your HIV uses only the CCR5 coreceptor.
How do CCR5 antagonists work?
CCR5 co-receptor antagonists prevent HIV-1 from entering and infecting immune cells by blocking CCR5 cell-surface receptor. Small molecule antagonists of CCR5 bind to a hydrophobic pocket formed by the transmembrane helices of the CCR5 receptor.
How do you take selzentry?
SELZENTRY tablets and oral solution are taken twice daily by mouth and may be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications. The recommended dosage of SELZENTRY differs based on concomitant medications due to drug interactions.
Does atazanavir cause nausea?
Symptoms may include: pain in the right or middle upper stomach area, fever, nausea and vomiting, or yellowing of the skin or the white part of your eyes.
Which medication should be avoided in combination with raltegravir?
Raltegravir: Raltegravir (400 mg once daily or 1200 mg twice daily) should not be coadministered with any aluminum- or magnesium-containing antacid.
What are the contraindications for Selzentry?
Selzentry is contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions ( 5.3 )]. Hepatotoxicity with allergic features including life-threatening events has been reported in clinical trials and postmarketing.
What is Selzentry used to test for?
Selzentry is recommended for patients with only CCR5-tropic HIV-1 infection. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on Selzentry [see Microbiology (12.4), Clinical Studies (14.1)].
What should I monitor when taking Selzentry?
Monitor patients for ALT, AST, and bilirubin prior to initiation of Selzentry and at other time points during treatment as clinically indicated [see Warnings and Precautions ( 5.1 )]. Selzentry tablets and oral solution are taken twice daily by mouth and may be taken with or without food.
When should Selzentry be used in the treatment of renal impairment?
Selzentry should be used in patients with severe renal impairment or ESRD only if they are not receiving a concomitant potent CYP3A inhibitor or inducer. However, the use of Selzentry in these patients should only be considered when no alternative treatment options are available.